ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ranibizumab

Also written as “ranibizumab”, “Ranibizumab 0.5 mg” and “rhuFab V2 (ranibizumab)”.

Its studies are mostly in Macular Degeneration · Macular Edema · Choroidal Neovascularization · Retinal Vein Occlusion · Vision Disorders, led by 16 companies.

Drug pageRanibizumab: every studyMany companies study it; this page follows only the 98 they lead. All 351 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 19, 200798 company-led studies, 6 open or runningNext primary completion: Feb 4, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only560 open or runningphase 4since Jul 19, 2007Jan 11, 2006none ahead
Hoffmann-La Rocheits history only244 open or runningphase 4since Jan 13, 2011Mar 24, 2003Feb 4, 2027phase 3 · NCT04657289
AbbVieits history only31 open or runningphase 4since Aug 31, 2011Oct 16, 2008Jul 2031phase 2 · NCT05210803
Samsung Bioepisits history only20 open or runningphase 2since Dec 11, 2023Dec 11, 2023none ahead
Santen Pharmaceuticalits history only20 open or runningphase 2since Oct 1, 2008Oct 1, 2008none ahead
AO GENERIUMits history only11 open or runningphase 3since Nov 30, 2020Nov 30, 2020none ahead
Bioeqits history only10 open or runningphase 3since Nov 19, 2015Nov 19, 2015none ahead
Cynosure Lutronicits history only10 open or runningphase 4since Nov 27, 2018Nov 27, 2018none ahead
Formyconits history only10 open or runningphase 4since Nov 25, 2024Nov 25, 2024none ahead
Incepta Pharmaceuticalsits history only10 open or runningphase 3since Mar 5, 2024Mar 5, 2024none ahead
QLT10 open or runningphase 2since Jun 25, 2007Jun 25, 2007none ahead

Also a collaborator on its studies: REGENXBIO, Stada Arzneimittel and MacuSight.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of QLT only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 25, 2007First study: phase 2 study in Choroidal NeovascularizationFirst studyNCT00492284 · 162 enrolled · United States, Canada

TargetBeta

VEGFA →read by rule
“A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule

Other programs on VEGFA

ProgramCompanyFurthest phaseStudies
BevacizumabruleHoffmann-La Rochephase 4250
afliberceptruleRegeneron Pharmaceuticalsphase 489
faricimabruleHoffmann-La Rochephase 417
ivonescimabruleAkesophase 348
pumitamigBioNTechphase 334
tivunatamigPfizerphase 315
suvemcitugruleSimcere Pharmaceutical Groupphase 36
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
surabgene lomparvovecAbbViephase 32
ABBV-1480RemeGenphase 32
HLX37Fosun Pharmaphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24

Studies

The one study QLT leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00492284Choroidal Neovascularization · United States, Canada2CompletedMay 2009162

How it is read

Names in the registry

  • “Ranibizumab”, 40 entries
  • “ranibizumab”, 18 entries
  • “Ranibizumab 0.5 mg”, 11 entries
  • “rhuFab V2 (ranibizumab)”, 6 entries
  • “Ranibizumab 0.5mg”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.